Asante Capital Group Celebrates 2023 Achievements, Extends Track Record of Successful Fundraises and Grows Global Team

As we enter 2024, Asante is pleased to announce another exceptional year, extending our track record of successful fundraising, strengthening our global presence and offerings, and facilitating expert discussions throughout 2023.

Despite a challenging fundraising environment, Asante supported 43 successful fund closes around the globe in various sectors, with the majority exceeding their targets. We also saw continued internal growth, with five managing director promotions and the doubling in size of our offices in Munich and Hong Kong. Additionally, Asante enhanced its existing secondaries offerings, advising on successful fund closes and expanding our global team. Asante also demonstrated our thought leadership in the PE space with our Asante Summer Series, where we facilitated discussions with industry experts on top trends in the current market.

“We are very proud of our track record raising funds and our commitment to providing the best solutions for our clients across the globe as they navigate the current economic environment and look to the future,” said Fraser van Rensburg, co-founder and Managing Partner at Asante.

“We are excited for what 2024 will bring as we continue to deepen our commitment to being the go-to trusted, independent advisor and partner,” said Warren Hibbert, co-founder and Managing Partner at Asante.

Read more here.

Asante Capital congratulates partner HighLight Capital (HLC) on the final closing of its flagship HLC USD Fund IV at US$550 million

We are delighted to share that HighLight Capital (HLC), a private equity firm focusing on venture and growth investments across healthcare and consumer health sectors in China, held the final close of its flagship HLC USD Fund IV at US$550 million.

Asante Capital congratulates partner Abingworth on the final closing of its new Clinical Co-Development Co-Investment Fund at $356 million

We are delighted to share that Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle (NASDAQ: CG), today announced the final closing of its new Clinical Co-Development Co-Investment Fund at $356 million.

Asante Capital congratulates its partner Norvestor on closing Norvestor IX SCSp (“Norvestor IX”) at its hard cap of €1.5 billion

We are delighted to share that Norvestor, a leading private equity firm in the Nordics, has closed Norvestor IX SCSp (“Norvestor IX”) at its hard cap of €1.5 billion, exceeding its €1.25 billion target, despite a challenging fundraising environment.